OXA(17-33) 是一种高效、选择性的 orexin-1 receptor (OX1) 激动剂。OXA(17-33) 对 OX1 (EC50=8.29 nM) 的选择性比 OX2 (187 nM) 高 23 倍。 OXA(17-33) 是一种具有高效能与 ...

NLS Pharmaceutics (NLSP) announced that its CEO Alex Zwyer, has issued a letter to shareholders, which read in part, “Over ...

AstraZeneca has ended work on an opioid use disorder (OUD) drug after the orexin 1 receptor antagonist demonstrated a drug-drug interaction with an antifungal during a phase 2 trial. The Big ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter TheraCryf plc has been awarded a European patent for its highly selective Orexin 1 receptor antagonist ...

NLS Pharmaceutics (NLSP) shared preclinical data demonstrating the potential of its dual orexin receptor agonist platform. AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed to ...

TheraCryf's highly selective Ox-1 receptor antagonist was acquired as part of its acquisition of Chronos Therapeutics Ltd in April 2024. An imbalance in Orexin production and stimulation of the ...

The brain receptors became “orexin-1” and “orexin-2.” The team prepared to publish its findings in Cell. But another group beat them to it. In early January 1998, a team of Scripps ...

are designed to target both orexin-1 and orexin-2 receptors while concurrently inhibiting cathepsins. Cathepsins play significant roles in a variety of physiological processes and may offer a ...

TheraCryf's highly selective Ox-1 receptor antagonist was acquired as part of its acquisition of Chronos Therapeutics Ltd in April 2024. An imbalance in Orexin production and stimulation of the ...

are designed to target both orexin-1 and orexin-2 receptors while concurrently inhibiting cathepsins. This unique approach aims to address the unmet therapeutic needs in narcolepsy and related ...